Scinai Immunotherapeutics Ltd. (SCNI) — SEC Filings

Latest SEC filings for Scinai Immunotherapeutics Ltd. (SCNI), explained in plain English.

Sentiment Overview: 7 bullish, 1 bearish, 38 neutral, 1 mixed

Recent Filings (47)

• SCNI Files 20-F for 2025; Financials Await Full Report Review — 20-F · 2026-04-01T07:36:13-04:00 [neutral] Risk: high
  Scinai Immunotherapeutics Ltd. (SCNI) filed its annual 20-F report on April 1, 2026, for the fiscal year ended December 31, 2025. This filing, SEC Accession No.
• 6-K Filing — 6-K · 2025-12-23T00:00:00.000Z [neutral]
• 6-K Filing — 6-K · 2025-12-02T00:00:00.000Z [neutral]
• 6-K Filing — 6-K · 2025-11-13T00:00:00.000Z [neutral]
• Scinai Immunotherapeutics Secures Israel Innovation Authority Grant — 6-K · 2025-10-06T00:00:00.000Z [bullish] Risk: low
  On October 6, 2025, Scinai Immunotherapeutics Ltd. announced it received a grant from the Israel Innovation Authority. This funding will be used to expand its f
• Scinai Immunotherapeutics Eyes Pincell srl Acquisition — 6-K · 2025-09-22T00:00:00.000Z [neutral] Risk: medium
  Scinai Immunotherapeutics Ltd. announced on September 22, 2025, that it is anticipating the signing of an option agreement to acquire Pincell srl, an Italian bi
• Scinai Secures Up to $10M Equity Line with Yorkville — 6-K · 2025-09-11T00:00:00.000Z [neutral] Risk: medium
  On September 10, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell
• Scinai Immunotherapeutics Files 6-K Report — 6-K · 2025-09-02T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. filed a Form 6-K on September 2, 2025, reporting information for the period ending June 30, 2025. The filing includes a press rel
• Scinai Immunotherapeutics Announces Funding and CDMO Growth — 6-K · 2025-06-12T00:00:00.000Z [neutral] Risk: low
  On June 12, 2025, Scinai Immunotherapeutics Ltd. announced new funding and growth in its Contract Development and Manufacturing Organization (CDMO) business. Th
• Scinai Immunotherapeutics Gets Italian Clearance for Pincell Acquisition — 6-K · 2025-06-05T00:00:00.000Z [bullish] Risk: medium
  On June 5, 2025, Scinai Immunotherapeutics Ltd. announced it has received Italian government clearance for its potential acquisition of Pincell S.r.l. This clea
• Scinai Immunotherapeutics Reports Q1 2025 Financials — 6-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. filed a Form 6-K on June 2, 2025, to report its Q1 2025 financial results, which were announced via press release on May 30, 2025
• Scinai Immunotherapeutics Files 2024 Annual Report — 20-F · 2025-05-07T00:00:00.000Z [neutral] Risk: medium
  Scinai Immunotherapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as BiondVax Pharmac
• Scinai Immunotherapeutics to Acquire Rare Disease Firm Pincell — 6-K · 2025-03-27T00:00:00.000Z [neutral] Risk: medium
  On March 27, 2025, Scinai Immunotherapeutics Ltd. announced it has signed an option agreement to acquire Pincell, a rare disease company. This acquisition inclu
• Scinai Immunotherapeutics Licenses VAX-24 Flu Vaccine — 6-K · 2025-03-24T00:00:00.000Z [neutral] Risk: low
  On September 26, 2024, Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to an unaffiliated U.S. private
• Scinai Immunotherapeutics Secures $10M Equity Line — 6-K · 2025-03-05T00:00:00.000Z [neutral] Risk: medium
  On March 5, 2025, Scinai Immunotherapeutics Ltd. announced a $10 million Standby Equity Purchase Agreement. This agreement provides the company with a flexible
• Scinai Immunotherapeutics Secures $10M Equity Line — 6-K · 2025-03-04T00:00:00.000Z [neutral] Risk: medium
  On March 3, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell up to
• Scinai Immunotherapeutics Reports Q3 2024 Results — 6-K · 2024-11-25T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on November 25, 2024, to report its Q3 2024 financial results and provi
• Scinai Immunotherapeutics Holds Annual Shareholder Meeting — 6-K · 2024-11-22T00:00:00.000Z [neutral] Risk: low
  On November 21, 2024, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,411,983
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Scinai Immunotherapeutics Files October 6-K Report — 6-K · 2024-10-15T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on October 15, 2024. This report is for the month of October 2024 and i
• Scinai Licenses Universal Flu Vaccine Candidate VAA437 — 6-K · 2024-09-26T00:00:00.000Z [neutral] Risk: medium
  On September 26, 2024, Scinai Immunotherapeutics Ltd. entered into a license agreement with an unaffiliated U.S. private company. This agreement grants the Lice
• Scinai Immunotherapeutics Files 6-K Amendment — 6-K · 2024-09-09T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. filed an amendment (Amendment No. 1) to its Report on Form 6-K on September 9, 2024. This filing is an update for the month of Se
• Scinai Immunotherapeutics Regains Nasdaq Listing Compliance — 6-K · 2024-08-29T00:00:00.000Z [bullish] Risk: low
  Scinai Immunotherapeutics Ltd. announced on August 29, 2024, that it has regained compliance with the Nasdaq Stock Market's listing requirements. This follows a
• Scinai Immunotherapeutics Restructures $29M Debt to Equity — 6-K · 2024-08-21T00:00:00.000Z [neutral] Risk: medium
  On August 21, 2024, Scinai Immunotherapeutics Ltd. announced the closing of a Loan Restructuring Agreement with the European Investment Bank. This agreement con
• Scinai Secures $2M Equity Commitment — 6-K · 2024-08-20T00:00:00.000Z [neutral] Risk: medium
  On August 20, 2024, Scinai Immunotherapeutics Ltd. announced a $2 million private equity commitment agreement with its largest existing shareholder. This agreem
• SC 13G/A Filing — SC 13G/A · 2024-08-20T00:00:00.000Z [neutral]
• Scinai Immunotherapeutics Reports Q2 2024 Results — 6-K · 2024-08-15T00:00:00.000Z [neutral] Risk: low
  On August 15, 2024, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its Q2 2024 financial results and provide
• Scinai Immunotherapeutics Restructures $29M Debt — 6-K · 2024-08-13T00:00:00.000Z [mixed] Risk: medium
  On August 13, 2024, Scinai Immunotherapeutics Ltd. announced a significant debt restructuring with the European Investment Bank. The company converted approxima
• Scinai Immunotherapeutics Holds Shareholder Meeting — 6-K · 2024-08-12T00:00:00.000Z [neutral] Risk: low
  On August 12, 2024, Scinai Immunotherapeutics Ltd. held an Extraordinary Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,349
• Scinai Immunotherapeutics Ltd. Updates Shareholder Meeting Proxy — 6-K · 2024-08-05T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on August 5, 2024, to provide a Notice to Shareholders regarding change
• Scinai Immunotherapeutics Reports Promising Psoriasis Model Results — 6-K · 2024-07-15T00:00:00.000Z [bullish] Risk: medium
  On July 15, 2024, Scinai Immunotherapeutics Ltd. announced promising in-vivo proof-of-concept results for its psoriatic human skin model. The company, formerly
• Scinai Gets Nasdaq Listing Extension — 6-K · 2024-07-08T00:00:00.000Z [neutral] Risk: medium
  Scinai Immunotherapeutics Ltd. announced on July 3, 2024, that the Nasdaq Hearing Panel has granted an extension for the company to regain compliance with Nasda
• Scinai Immunotherapeutics Files Updated Business Presentation — 6-K · 2024-06-14T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on June 14, 2024, to furnish an updated business presentation. The pres
• Scinai Immunotherapeutics Regains Nasdaq Bid Price Compliance — 6-K · 2024-06-13T00:00:00.000Z [bullish] Risk: medium
  On June 7, 2024, Scinai Immunotherapeutics Ltd. announced it has regained compliance with Nasdaq's minimum $1.00 bid price requirement. The company is continuin
• Scinai Immunotherapeutics Faces Nasdaq Delisting Warning — 6-K · 2024-05-28T00:00:00.000Z [neutral] Risk: medium
  Scinai Immunotherapeutics Ltd. received a Nasdaq staff determination letter on May 24, 2024, indicating non-compliance with shareholders' equity listing require
• Scinai Immunotherapeutics Files 2023 Annual Report — 6-K · 2024-05-15T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. announced on May 6, 2024, the publication of its fiscal year 2023 financial statements and the filing of its Annual Report on For
• Scinai Immunotherapeutics Faces Nasdaq Delisting, Plans Appeal — 6-K · 2024-05-07T00:00:00.000Z [bearish] Risk: high
  Scinai Immunotherapeutics Ltd. announced on May 6, 2024, that it received a Nasdaq delisting notification. The company plans to appeal this decision and has app
• Scinai Immunotherapeutics Files Updated Business Presentation — 6-K · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on April 25, 2024, to furnish an updated business presentation. The pre
• Scinai Immunotherapeutics Files Updated Business Presentation — 6-K · 2024-04-16T00:00:00.000Z [neutral] Risk: low
  Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) has filed a Form 6-K on April 16, 2024, to provide an updated business presentation. Thi
• Stone Files SC 13D for Scinai Immunotherapeutics — SC 13D · 2024-03-12T00:00:00.000Z [neutral] Risk: medium
  On March 12, 2024, Daniel E. Stone filed an SC 13D form regarding Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.). The filing indicates
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• Daniel E. Stone Discloses 12.96% Stake in Scinai Immunotherapeutics — SC 13G/A · 2024-01-24T00:00:00.000Z [bullish]
  Daniel E. Stone, an individual investor, has filed an Amendment No. 2 to Schedule 13G, reporting a beneficial ownership of 624,000 Ordinary ADS Shares in Scinai
• Scinai Immunotherapeutics Updates Corporate Presentation for January 2024 — 6-K · 2024-01-18T00:00:00.000Z [neutral]
  Scinai Immunotherapeutics Ltd. filed a 6-K on January 18, 2024, to provide an updated corporate presentation for January 2024. This presentation, furnished as E
• SCINAI IMMUNOTHERAPEUTICS UPDATES INVESTOR PRESENTATION — 6-K · 2024-01-09T00:00:00.000Z [neutral]
  Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) filed a 6-K on January 9, 2024, to provide an updated corporate presentation for January 2024. This presentation,
• Scinai Raises $1.69M from Warrants, CEO Sends Shareholder Letter — 6-K · 2024-01-04T00:00:00.000Z [neutral]
  Scinai Immunotherapeutics Ltd. filed a 6-K on January 4, 2024, announcing two key events: a letter to shareholders from CEO Amir Reichman and the closing of war
• Scinai Immunotherapeutics Raises $1.69M from Warrant Exercises — 6-K · 2024-01-02T00:00:00.000Z [bullish]
  Scinai Immunotherapeutics Ltd. announced on December 29, 2023, that it received $1.69 million in gross proceeds from the exercise of outstanding warrants. This
• Sabby Volatility Fund Discloses 220,663 Scinai Immunotherapeutics ADSs — SC 13G/A · 2024-01-02T00:00:00.000Z [neutral]
  Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, filed an amended SC 13G/A on January 2, 2024, disclosing its beneficial ownership in